INDEX

A
Abtropfung hypothesis
of melanocyte histogenesis, 7
of the origin of melanocytic nevi, 51
Acanthoma, large-cell, transition of solar lentigo to, 41
Acquired dermal melanocytosis, of the face and extremities, 201
Acquired melanocytic nevi, common, 55–64
Acral melanomas, 280–284
defined, 241
distribution of, by skin color, 248–249
Acral nevus, melanocytic, 89–90
Activating transcription factor 1 (STF-1) gene, on chromosome 12, translocation of, in elear-cell sarcoma, 327
Adipocytes, accumulation of, in some nevi, 66
Adnexal involvement, of Spitz nevi, 160
Age
at diagnosis of melanoma associated with congenital melanocytic nevi, 113
as a factor in differential diagnosis of Spitz nevus, 170
and melanoma arising from small congenital melanocytic nevi, 131
and occurrence
of acral melanoma, 280
of ancient melanocytic nevus, 65
of balloon cell melanoma, 90
of Becker’s melanosis, 44–45
of clonal nevi, 98
of congenital nevi in the first year of life, 115
of desmoplastic melanoma and desmoplastic-neurotropic melanoma, 290
of halo nevi, 90
of melanocytic nevi, 55
of melanoma, 136–144
of small cell melanomas, 314–315
of solar lentigines, 40
of solar melanoma, 248, 267–275
of subungal melanoma, 284
of vulvar melanoma, 98
and prognosis, in malignant melanoma, 380
and recurrence of Spitz nevi, 188–190
Agminate Spitz nevi, 150–151
AgNORs (silver-staining nucleolar organizer region) counts of, as a prognostic factor, 382
of Spitz nevi, 171
Albright syndrome, melanotic macules associated with, 40
Alternative reading frame (ARF) tumor suppressor gene of CDKN2A penetrant melanoma locus, 21
Amelanotic blue nevus, 204–206
Amelanotic melanoma, 249, 330
American Joint Committee on Cancer (AJCC)
classification of satellite and in-transit metastases of malignant melanoma, 357–358
stage III disease, 383–385
stage IV disease, 358
staging of localized disease, 373
Anatomic level of tumor invasion in the dermis and subcutis, 375–376
Anatomic site
importance of, in classifying melanomas, 242–243
of malignant melanoma metastases, and prognosis, 386
of the primary melanoma, and prognosis, 380
of Spitz nevi, 149
as a factor in differentiating melanoma from, 170
Ancient melanocytic nevi, 65–66
Ancillary studies, for evaluation of melanocytic lesions, 13–16
of recurrent Spitz nevi, 193–194
Aneuploidy, and prognosis, 381
Angiogenesis
and prognosis in cutaneous malignant melanoma, 379
in zones of regression of melanomas, 339
Angiomatoid Spitz nevus, variant of desmoplastic Spitz nevi, 175
Angiotropic tumor aggregates, as microscopic satellites, 261
Angiotropism
of desmoplastic melanoma and desmoplastic-neurotropic melanoma, 293
of melanomas, 301–302
of Spitz nevi, 160
Angio-tumoral complex, 302
Animal-type melanoma, 331–333
Architecture
of atypical nevi, 75–76, 124–125
of cellular blue nevi, 210
general, of melanocytic nevi, 64
of pigmented spindle cell nevi, 180–185
Atypical intradermal melanocytic proliferation, with indeterminate biologic potential, 345–346
Atypical melanocytic nevi (AMN), 263–265
Differential diagnosis

Diagnosis

of atypical nevi, 75–86
of melanoma, criteria for, 239–244
of conventional microinvasive, 257–260
of intraepidermal, 287
of malignant, 358–370
of solar intraepithelial melanocytic proliferation, 278–279
of Spitz nevus, 161–162

Special techniques for, 171–175

Differential diagnosis

of acral melanoma, 287
of acral nevi, 89–90
of amelanotic blue nevi, 205–206
of atypical nevi, 86–88
of balloon cell lesions, 90
of balloon cell melanoma, 331
of Becker’s melanosis, 46
of blue nevi
of atypical cellular, 216
of common, 204
of compound, 209
of epithelioid, 209
of malignant, 327
of sclerosing, 204
of target, 220

of cafe-au-lait macules, 40
of clear-cell sarcoma, 328
of clonal nevi, 100–103
of conventional melanomas with intraepithelial components, 261
of dermal melanocytic tumor, 333
of desmoplastic melanoma and neurotropic melanoma, 300–301
of desmoplastic Spitz nevi, 175–178
of freckles, 37
of halo nevi, 92–94
of intraepidermal Spitz nevi, 163–171
of lentigo maligna, 274–275
of lentigo simplex, 54–55
of melanocytic nevi
of the genital skin, 98
of the melanocytic nevi
with phenotypic heterogeneity, 232–233
recurring, 96
of melanoma associated with dermal nevi, 322
of melanoma with little adjacent intraepidermal component, 267

of Mongolian spots, 200
of mucocutaneous melanotic macules and lentigines, 49
of myxoid melanoma, 331
of nevoid melanoma, 309–311
of nevus spilus, 94–96
of recurrent Spitz nevus, 195–196
of regressed melanoma, 341
of regressed nevus, 343
of regression in melanoma, 342–343
of small cell melanoma, 313
of small congenital melanocytic nevi, 131
of solar intraepidermal melanocytic proliferations, 44
of solar lentigo, 41–42
of solar melanocytic hyperplasia, 279
of spindle cell nevi
pigmented, 185
plexiform, 236–237
of Spitz nevus, 150–151
with halo reaction, 180
of Spitzoid melanoma, 319
of verrucous melanoma, 312
5,6-Dihydroxyindole units, in eumelans, 1
DNA, abnormal content of in congenital melanocytic nevi, 133–134
in Spitz nevus, 173
DNA mismatch repair genes, expression in atypical nevi and melanomas, 74
DNA-ploidy, as a prognostic factor in malignant melanoma, 381
DNA repair, defective, in solar melanomas, 267

E

Ectasia, in zones of regression of melanomas, 339
Edema, in Spitz nevus, 160
Electron microscopy of melanocytes for differential diagnosis, 16–17
for observing morphology, 3–4
for observing the morphology of desmoplastic melanoma, 299
Embryology, of melanocytes, 8–9
Enzyme histochemistry, for evaluating melanocytic lesions, 13–14

Epidemiology

descriptive, of malignant melanoma, 238–239
of Spitz nevus, 149

Epidermal changes
atrophy in solar melanomas, 251
in congenital melanocytic nevi, 123–124
hyperplasia in melanomas from acral skin, 251

Epidermal growth factor (EGF) receptor, 73–74
Epidermal melanin unit, defined, 1
Epidermal nevus, differentiating from Becker’s melanosis, 46
Epithelioid cell
atyypical nevus, 86
histiocytoma, differentiating from Spitz nevus, 171
morphology of, 359–364
variant, of blue nevi, 206
Epithelioid-cell type melanomas in childhood, 141–142
Epithelioid melanocytes (type A cells) appearance of, 7
of Spitz nevus, 153–157
zonation of, 158–159
Epithelioid melanoma cells, 260–261
in desmoplastic melanoma and desmoplastic-neurotropic melanoma, 291
and Pagetoid scatter, 254
Epithelioid melanomas, diagnosis with melanocyte differentiation markers, 14

Etiology

of balloon cell melanoma, 330–331
of childhood melanoma, 140–141
of depigmentation in halo nevi, 92–94
Eumelanin, 1
production of, binding of -melanocytic-stimulating hormone in, 28–29
Eumelanosomes, stages of formation of, 3–4
Evaluation, of melanoma, ancillary techniques for, 13–16
Ewing sarcoma oncogene, translocation in clear-cell sarcoma, 327
EWS-ATF1 fusion gene, in melanoma of soft parts, 368
Excisional biopsies, 11
Extravascular migratory metastasis, 302
Eyelid, congenital divided nevus of, 113–114

F

Familial aggregation, of congenital melanocytic nevi, 114
Familial melanoma susceptibility loci, 20–29
major melanoma genes of, 32
Fas (CD95), role in cellular homeostasis, utilizing apoptosis, 30–31
Fasl, upregulation of the soluble form, interaction with membrane Fasl, 31
Feedback loops, integration of the p16/retinoblastoma and alternate reading frame/p53 path, 27
Fibrotic papillary dermis, of atypical melanocytic nevi, entrapment of atypical nevus cells in, 264
Fibrous histiocytoma, malignant, distinguishing from desmoplastic melanoma, 301
Fibroxanthoma, atypical, distinguishing from desmoplastic melanoma, 301
Field effect, from melanoma, 279
Fixation, of skin excisions, 11
Freckles (ephelides), 37-38
Fluorescence in situ hybridization (FISH) for identification of clear-cell-sarcoma, 328
of HRAS gene mutation in Spitz nevi, 175
for study of acral melanomas, 279-280
Fontana-Masson stain, 13
Frozen sections, for assessment of margins, 12-13
G
Gender, and prognosis in melanomas, 380
Genes
alterations at the CDKN2A locus, 23-24
of melanoma, major, 21
N-ras, association with congenital melanocytic nevus and melanoma, 133-134
See also Chromosomes; Inheritance
Genetic basis, for growth and development of nevi, 51-52
Genetic control
of development of nevi, 55-56
of the risk for melanoma, 69
of the type of melanin pigmentation, 1
Genetic pathology of melanoma, 20-36
Genital skin, melanocytic nevi of, 96-100
Genomic structure of CDKN2A/ARF, 23
Giant nevus cells
intradermal, 61
in Spitz nevi, 159
gp100
antibody to, for recognizing metastatic tumor deposits in sentinel lymph nodes, 358
premelanosomal glycoprotein, 14-15
Grading
of architectural disorder in atypical nevi, 86
Histologic features
of acral nevus, 89
of balloon cell lesions, 90
of blue nevus and variant blue nevi, 223-225
of clonal nevi, 98-100
of halo nevi, 92
of melanocytic nevi of the genital skin, 98
of metastatic melanoma, 358
Histologic variations within atypical nevi, 86
Histomorphologic criteria, defining conventional invasive melanomas, 260-266
Histopathologic criteria for conventional invasive melanomas with little intraepidermal component, 266
for diagnosis of melanoma, 240-241
for identifying acral melanoma, 282-284, 287-288
for identifying angiotropic melanoma, 302
for identifying balloon cell melanoma, 330
for identifying blue nevus amelanotic, 205
for identifying clear-cell sarcoma, 328
for identifying congenital melanocytic nevi, 115-124
for identifying conventional melanomas, 249-256
for identifying dermal melanocytic tumor, 333
for identifying dermal melanocytoses, 202
for identifying desmoplastic melanoma and desmoplastic-neurotropic melanoma, 291-293
for identifying desmoplastic Spitz nevi, 175
for identifying melanoma associated with dermal nevi, 320-321
for identifying Mongolian spots, 200
for identifying neurotropic melanoma, 295
for identifying nevoid melanoma, 304-309
for identifying pigmented spindle cell nevi, 180-185
for identifying pilar neurocristic hamartoma, 220
for identifying plaque-type blue nevi, 218
for identifying sclerosing blue nevi, 204
for identifying small cell melanoma, 313
for identifying solar melanoma, 271-274
versus melanomas, 190-193
for identifying Spitz nevi, 151-158
of solar intraepidermal melanocytic proliferations, 44
Histopathologic features
of atypical nevi, 75
of Becker’s melanosis, 46
of café-au-lait macules, 39–40
of deep penetrating nevi, 233
of ephelides, 37
of lentigo simplex, 54
of melanocytic nevi, 57–61
with phenotypic heterogeneity, 226–228
of melanomas in childhood, 141–144
of mucocutaneous melanotic macules and lentigines, 48–49
of plexiform spindle cell nevi, 235–236
of solar lentigo, 41
Histopathologic reporting
of atypical nevi, 88–89
of melanoma, 346
Historical perspectives, on classification of melanoma, 242–244
HMB-45 tumor marker
for distinguishing desmoplastic melanoma from other lesions, 300
for melanocytes, 14–15
negative, in neurotropic melanoma, 295–296
Hochsteigerung hypothesis, of melanocyte histogenesis, 7
Homogentisic acid pigment, 2
Hormones
association of androgen with Becker’s melanosis, 44
association of estrogen with papillomatous changes in nevi, 64–65
Host response
in atypical nevi, 85
in invasive melanoma, 261
in malignant melanoma, effect on prognosis, 378
HRAS gene mutation, fluorescence in situ hybridization (FISH) for identifying, 175
Hutchinson melanotic freckle, melanoma associated with, 267–275
Hydroxyl radicals from irradiation of pheomelanin, 1
Hyperkeratosis in conventional melanomas, 251
Hyperpigmentation of the basilar epidermis, in lentigo simplex, 54
Hypopigmentation of completely regressed melanoma, 341

Immunohistochemistry
for evaluating desmoplastic melanoma, 299
for evaluating desmoplastic-neurotropic melanoma, 295–296
for evaluating melanocytic lesions, 14–16
of Kamino bodies in Spitz nevi, 159
of metastatic melanoma distinguishing from nodal nevi, 368
with epithelioid or spindle cell morphology, 362
of sentinel lymph nodes, 358
of Spitz nevi, 171–172
Immunolabeling, of metastatic tumors, PECAM-1 and VEGF, 386
Immunophenotype analysis, of infiltrating cells of halo nevi, 92
Immunostaining
for melanocyte differentiation antigens, 199–200
unusual results associated with melanomas, 16
Incidence
of congenital melanocytic nevi, 111
of Spitz nevi, 149
Inflammatory infiltrate, perivascular, in Spitz nevi, 160
Inflammatory patterns, of congenital nevi, 121–123
Inflammatory response, participation of melanocytes in
Inheritance
autosomal dominant
of freckling, 37–38
of neurofibromatosis, 40
See also Genes; Genetic entries
INK4 gene family, 23
Ink-spot solar lentigo, clinical features of, 41. See also Solar lentigo
Institutional review board (IRB), consent of, to obtain tissue for research, 13
Interobserver concordance
in judging clinical atypia of nevi, 70–71
study of Spitz nevus criteria, 166–168
in judging histologic diagnosis of atypia of nevi, 75
Intraepidermal component
missing, in malignant blue nevus, 323
of Spitz nevi, atypical features of, 163
Intraepidermal epithelioid cells, melanocytic proliferations of, 262–263
Intraepidermal melanocytic proliferation atypical, 343–346
disordered, in atypical nevi, 78–82
with intermediate biologic potential, 345–346
Intraepidermal Pagetoid spread, of melanocytes, 125
Intraepidermal pigmented spindle cell, differentiating from intraepidermal melanoma, 263
Intraepithelial melanoma, histopathologic features of, 249
In-transit metastases, defined, 357–358
J
Junctional cleavage, in Spitz nevi, 160
Junctional nests
of the basal epidermal zone, 57
of Spitz nevi, 155–157
Junctional nevus
defined, 57–61
lentiginous, defined, 55
transition of melanocytes to, 52
K
Kamino bodies
in pigmented spindle cell nevi, 183
in Spitz nevi, 159
Keratinocytes, transfer of melanin pigment particles to, 1
Keratoses
lichenoid, 341
transition of solar lentigo to, 41
melanomas resembling, 249
reticulated seborrheic, transition of solar lentigo to, 41
Ki-67 nuclear antigen
assessing melanocytic lesions using, 16
immunolabeling of, to assess proliferation rate, 382
levels of, and stage of melanoma, 383
Knockout models, CDKN2A deficient mice, 25
L
Lactate dehydrogenase (LDH) levels and prognosis in metastatic malignant melanoma, 358
Lamellar fibroplasia
in atypical nevi, 86
in melanocytic nevi of the genital skin, 98
Leiomyosarcoma, cutaneous, distinguishing from desmoplastic melanomas, 301
Lentigines, mucocutaneous, 46–49
Lentiginous compound nevi, atypical, differentiating from small cell melanoma, 313
Lentiginous melanocytic hyperplasia, defined, 3
Lentiginous melanocytic nevi, 275–280
Lentiginous melanocytic proliferation (LMP), 345
falling short of melanoma in situ, 271–274
of the sun-damaged skin, 254
Lentiginous melanomas
association with desmoplastic melanoma and desmoplastic-neurotropic melanoma, 291
overlap with Pagetoid melanomas, 265
Lentiginous nevi
differentiating from atypical nevi, 86–88
differentiating from solar lentigo, 41
histopathologic features of, 57
Lentiginous pattern
in conventional melanomas, 254
differentiating variants of, 265
Lentigo maligna melanoma, 141–142, 254,
267–275
definition of, 42–44
differentiating from atypical nevi, 87
punch biopsies of, 11
similarities with pigmented spindle cell nevus, 185
See also Solar melanoma
Lentigo malin des vieillards of Dubreuilh,
Leukoderma acquisitum centrifugum.
Leptomeningeal melanoma, 130
Lichen sclerosus, melanoma associated
Lentigo senilis.
Lentigo simplex, 40–44, 54–55
Location, of melanocytes in the skin,
Loss of function, of CDKN2A and ARF
Longitudinal melanonychia, 287–288
Lipofuscin (wear-and-tear pigment), 2
Liver spot.
Light microscopy, to observe the
Lichenoid keratosis, 341
Leptomeningeal melanoma, 130
Leukoderma acquisitum centrifugum. See Halo nevus
Lichen sclerosus, melanoma associated with,
Lichenoid keratosis, 341
transition of solar lentigo to, 41
Lichenoid pattern, in regressed melanomas,
341–342
Light microscopy, to observe the
morphology of melanocytes, 2–3
Leptin (leptin receptor, gp130), 2
Lipofuscin (wear-and-tear pigment), 2
Liverspot. See Solar lentigo
Location, of melanocytes in the skin,
defining melanocytic nevi in terms of,
Locoregional metastases, 357–358
Longitudinal melanonychia, 287–288
Loss of function, of CDKN2A and ARF loci, 25
Loss of heterozygosity
bracketing the CDKN2A locus on chromosome 9p in atypical nevi, 25
on chromosome 9p, in Spitz nevus, 175
of the neurofibromatosis 1 gene, in neurotropic melanoma, 299
Lupus erythematosus, cutaneous,
distinguishing from regression of melanomas, 341
Lymphatic invasion by Spitz nevus, 160
Lymph nodes
benign metastasis to, in congenital blue nevus, 324
involvement of, by blue nevi, 216–217
metastasis to, and prognosis in malignant melanoma, 383–385
See also Metastasis
Lymphocytes
resemblance of type B melanocytes to, 7
response to microinvasive melanomas, 260
Lymphocytic cells (type B nevus), 61
M
M2–7C10 antibody, to the Mart-1 melanoma cell line, 15
Macroglobules, melanin, in café-au-lait macules, 39–40
Macromelanosomes, association with melanocytic lesions, 2
Macular phase, of acral melanoma development, 280–282
Major histocompatibility complex (MHC), role in apoptosis of melanoma cells, 31
Malignant blue nevus (MBN), 128,
322–327
differentiating from cellular blue nevus, 216
Malignant degeneration of congenital melanocytic nevi, 114
Malignant epithelioid schwannoma, associated with congenital melanocytic nevi, 128
Malignant fibrous histiocytoma,
distinguishing from desmoplastic melanoma, 301
Malignant melanoma, 238–356
differentiating halo nevus from, 94
Malignant melanoma of soft parts, 327–328
Malignant neuroectodermal tumor,
289–301
Malignant Spitz nevus, defined, 162
Management of cohesive cellular nodules, 346
Mapping of melanoma genes, 21–26
Markers
A-103, for identifying human melanoma cells, 15
HDM2, prognostic significance of, 16
Mart-1
for recognizing metastatic tumor deposits in sentinel lymph nodes, 358
for Spitz nevus, 171
Melan A
for identifying melanocytes, 15
prediction of outcome from levels of, 383
for recognizing metastatic tumor deposits in sentinel lymph nodes, 358
for Spitz nevus, 171
Melanin pigment, 1–2
Melanin stains, 13
Melanin-stimulating hormone (MSH), 1
Melanocortin 1 receptor (MC1R), 28–29
association with freckles, 37
mediation of the response to ultraviolet light by, 21
role in phenomelanin synthesis, versus eumelanin synthesis, 32
Melanocytes, 1–10
in ephelides, size and appearance of, 37
large epithelioid, in Spitz nevus, 151–158
spindle-shaped, in Spitz nevus, 151–158
Melanocytic nevi acquired, 7–8, 51–110
comparison with nevoid melanoma, 310
congenital. See Congenital melanocytic nevi
conventional melanomas associated with, 261
differentiating from lentigo simplex, 55
with focal dermal epithelioid cell components (MNPFDEC), 230–233
of the genital skin, 96–100
with phenotypic heterogeneity, 223–237 defined, 225–226
recurrent, diagnosing, 345
status of CDKN2A in, 25
melanocyte differentiation, for evaluating sentinel lymph nodes, 357
NKI/C3, for identifying melanocytic lesions, 15–16
p75 neurotrophin receptor, 15, 291
T311 antibody to tyrosinase, for melanocytes, 15
tyrosinase-related protein 1, for melanocyte differentiation, 15
See also HMB45; S-100 protein
Melanocytic nuclear volume, and prognosis, 381
Melanocytic proliferation, benign, pattern of, 3
Melanoma in dermis, distinction from dermal nevus cells, 345–346
Melanoma in situ
criteria for defining, 271–274
criteria for differentiating from solar intraepidermal melanocytic proliferations, 44
histopathologic data for diagnosing, 249
threshold for diagnosing, 254–256
Melanoma of soft parts (MMSP), t(12;22)
Melanomas
association with nevi, 66–89
association with nevus of Ota involving the eye, 201
childhood, and giant congenital nevi, 140–141
criteria for differentiating from atypical nevi, 87
development of, in congenital nevi, 126–134
primary cutaneous, versus melanoma metastatic to the skin, 364
primary mucosal, versus melanoma metastatic to the skin, 364–366
Melanoma with nodular component, 249
Melanonychia striata, 57, 287–289
Melanosis, in metastatic melanoma, 358
Melanotic macules
Melasma
Melanoma of the nail apparatus, 284–289
Melanoma in situ
Metastasis
Melanoma of soft parts (MMSP), t(12;22)
Melanomas
Melanotic macules
Melanocytic proliferation, benign, pattern of, 3
Melanocytes, enzymes of, 3–4
Melanocytic nuclear volume, and control of metastasis by, 30
inactivation of, and neoplastic progression, 21
Memorial Sloan-Kettering Cancer Center, data on satellite metastases, 357
Meningeal melanoma, neurocutaneous melanosis as a precursor to, 114–115
Merkel cell carcinoma, small cell melanoma mimicking, 312–314
Mesenchymal tumors, arising from giant congenital melanocytic nevi, 131
Metastasis
of desmoplastic melanoma and desmoplastic-neurotropic melanoma, 300
distally acting melanoma loci involved in, 29–30
of malignant melanoma, 357–371
of melanoma distinguishing from nevoid melanoma, 310–311
to a fetus, 134
with unknown primary site, 368–369
of radial and vertical growth phases, 242–243
of Spitz tumors, 171
visceral, sites in malignant melanoma, 358
See also Lymph nodes
Metastatic malignant melanoma, 357–371
MIB-1 labeling index, for distinguishing melanomas and Spitz nevi, 16
Microinvasive melanoma
conventional, 256–260
regression in, 336–337
Micrometastatic disease, as a prognostic factor, 375
Microphthalmia transcription factor (MITF)
expression of, and prognosis in malignant melanoma, 383
as a marker for melanocytes, 15
Microsatellite instability near the CDKN2A locus, 74
Microscopic metastases, survival rate, 380
Microscopic satellites
of invasive melanomas, 261
prognosis predicted from, 377–378
Minimal deviation melanoma (MDM), 302–303, 379
Minor susceptibility melanoma loci, 32
Mitosis
dermal, in nevoid melanoma, 309
rate of, and prognosis in cutaneous malignant melanoma, 375–376
in Spitz nevi, 159
Models
of histogenesis of melanocytic nevi, 51–52
prognostic, in malignant melanoma, 386–388
Mohs micrographic surgery, for basal cell and squamous cell carcinoma treatment, 12
Molecular pathology of melanoma, 20–36
Molecular pathways, and the development of melanoma, 31–32
Moles. See Common acquired nevi
Mongolian spot, 200
Monoclonal antibodies
A-103, for identifying human melanoma cells, 15
for identifying human melanoma cells, 16
See also Markers
Morphologic features, of cellular blue nevi, 214–215
Morphology
of melanocytes, 2–4
of metastatic melanoma, 359
Mortality from cutaneous melanoma, among white populations, 238–239.
See also Survival rate
Mucin, interstitial accumulation of, in nevi, 66
Mucosal blue nevi, 220
Mucosal melanoma, 335–336
Mulberry-type giant cells, 61
Multiple lentigines, syndromes associated with, 54
Multiple melanomas
CDKN2A mutations in, 24
primary, incidence of, 368
Multiple Spitz nevi, 150–151
Multiple tumor suppressor 1 (MTS1), identification with p16, 22
Mutagenic agents, expression of 14pARF protein by, 26
Mutation analysis, of CDKN2A/ARF, 23–25
Myxoid melanoma, 331
Myxoid stromal reaction, in metastatic malignant melanoma, 362–363
Myxomas, distinguishing from desmoplastic melanomas, 301
N
National Institutes of Health (NIH), definition of nevus with architectural disorder and cytologic atypia, 68
Natural history of desmoplastic melanoma and desmoplastic-neurotropic melanoma, 299–300
Neoplasms, melanocytic nevi as, 51
Nerve growth factor (NGF) receptor, expression of, and prognosis in conventional malignant melanoma, 383
Nerve sheath tumors, distinguishing desmoplastic-neurotropic melanoma from, 301
Nested intraepidermal melanocytic proliferation, in conventional melanomas, 256, 345
Nests/nested pattern
distribution of, in atypical nevi, 82–83
junctional of the basal epidermal zone, 57
of Spitz nevi, 155–157
in melanoma, distinguishing from melanocytic nevi, 265–266
of nevocellular nevi, 7
Neural nevus, 94
Neurocristic hamartoma, 219–220

Index
Neurocutaneous melanosis (NCM), 111, 126
association with congenital melanocytic nevi, 114–115
Neuroectodermal tumors, 289–290
Neurofibromatosis (von Recklinghausen’s disease), density of melanocytes in café-au-lait macules and normal skin, 39–40
Neurofibromatosis 1 gene, loss of
Neuromelanin, accumulation of, in
Neurothekeoma
cellular, differentiating from Spitz nevus, 171
distinguishing from desmoplastic melanoma, 300–301
Neurotized nevus
differentiating from a neurofibroma, 94
melanocytic, 66
Neurotropic melanoma (NM), 290, 293–301
Neurotropic tumor aggregates, as
Nevoid melanoma, 303–311
Nevoid melanosis. See Becker’s melanosis
Nevis cells, morphology of, 7
as the site for melanoma development, 239
Nevis fusocaeuleus acromiodeltoideus, 201–202
Nevis fusocaeuleus ophthalmonomaxillaris, 200–201
Nevis fusocaeuleus zygomaticus, 201
Nevis of Ito, 201–202
Nevis of Ota, 200–201
Nevis planus (Speckled lentiginous nevus), 94–96
NKI/C3 monoclonal antibody, for
identifying melanocytic lesions, 15–16
Nodal nevus versus metastasis, 366–368
Nodular melanoma, 243
acral melanoma as, 282
defined, 266
Nomenclature
of borderline lesions, 343–346
defined, 53
of p16, 22
terminology for describing the Spitz nevus, 148–149
Nonmelanocytic tumor, differentiating from metastatic melanoma, 359–364
N-ras gene, association with congenital melanocytic nevi and melanoma, 133–134
Nuclear atypia
and architectural disorder, 75
continuum of, 83–85
Nuclei, of melanocytes, electron microscopic appearance of, 3
Nucleolar organizer regions (NORs)
and prognosis, 382
of Spitz nevi, 171
See also AgNORs
Nucleus of melanocytes, appearance under light microscopy, 3
O
Oncogenes
CDK4, 21
metastasis promoted by, 29–30
Outcomes, in recurrent Spitz nevus, 196
P
p14ARF, gene product of the alternate reading frame ARF, 23
p16 (CDKN2A). See CDKN2A (p16)
p53, activation of, by expression of p14ARF in the S phase of cell division, 27
p75 neurotrophin receptor (p75NR)
marker for desmoplastic melanoma and desmoplastic-neurotropic melanoma, 291
marker for spindle cell melanomas, 15
Paget’s disease, differentiating junctional Spitz nevus from, 164
Pagetoid melanocytosis
in conventional melanomas, 253–254
defined, 53
Pagetoid melanoma
anatomic sites of, 247–248
characteristics of, compared with pigmented spindle cell nevi, 189
Pagetoid pattern
and diagnosis of conventional melanomas, 251–254
diagnosis of melanomas with intraepidermal components, 261–265
Pagetoid proliferation, defined, 3
Pagetoid scatter
in acral nevi of the palms and soles, 89
defined, 53
in melanocytic nevi, recurrent, 96
Pagetoid Spitz nevus, 163
Pagetoid spread
association with melanomas of sun-exposed skin, 251
in conventional melanomas, 251–254
intraepidermal, of melanocytes, 125, 343–345
in pigmented spindle cell nevi, 185
in Spitz nevi, 157
intraepidermal, 159–160
Papillary dermis, invasion of, by in situ melanomas, 256
Parakeratosis, in conventional melanomas, 251
Patchlike blue nevus, 217
Pathologic factors, and prognosis, in malignant melanoma, 374–380
Penetration
of familial melanoma loci, 20
of germline mutations in CDKN2A, 24–25
minor, of familial melanoma genes, 27–29
Perinevoid leukodermia. See Halo nevus
Perinevoid vitiligo, See Halo nevus
Peutz-Jeghers syndrome, lentigines of the oral mucosa and vermilion border in, 47
Phaeomelanosomes, development of, stages in, 4
Phenotypes, histomorphologic, of neuroectodermal tumors, 290
Phenotypic heterogeneity, and nomenclature, 223–225
Pheomelanin, 1
production of, in response to low-affinity binding of melanocortin ligands, 28–29
synthesis of, promotion by melanocortin 1 receptor polymorphisms, 32
Photochemotherapy (PUVA), lentigo induced by, 41
Photoprotection, by eumelanin, 28
Pigmentation, of Spitz nevi, 160
Pigmented actinic keratosis, differentiating from solar lentigo, 41–42
Pigmented hairy epidermal nevus. See Becker’s melanosis
Pigmented spindle cell nevus (PSCN), 180–185
with atypical features, 183–185
intraepidermal, differentiating from intraepidermal melanoma, 263
Index

Pigmented spindle cell variant, of solar melanoma, 271–274
Pigment incontinence, in desmoplastic melanoma, 291
Pilar neurocristic hamartoma, clinical features of, 219–220
Plaque-type blue nevus, 217–219
Pleomorphism, of nevus cells, 61
Plexiform spindle cell nevus, 233–237
Proliferation index of nevi and melanomas, 74
Proliferation rate of Spitz nevi, compared with melanomas, 171–172
Proto-oncogenes, 20
Pseudomelanosis coli, pigment of, 2
Punch biopsies of cutaneous pigmented lesions, 11
R
Radial growth phase (RGP) of melanoma, 242–243
Ras protein, upregulation of, 31
Recurrent
of clear-cell sarcoma, 328
of desmoplastic melanoma, 300
local, and prognosis, 381
of malignant melanoma, 357
of melanotic nevi, 88, 96
of Spitz nevi, 185–196
Red hair and freckle gene, and the risk of melanoma, 27–29
Regression
effects of, on prognosis in melanoma, 376–377
of halo nevi, 92
of melanomas, 336–343
invasive, 261
leading to metastatic melanoma with unknown primary site, 368
microinvasive, 260
Pagetoid, 248
Regulation, of melanogenesis, 1
Relative risk of melanoma association with polymorphisms of the melanocortin 1 receptor, 29
relationship with the numbers of nevi, 71
Research, tissue for, 13
Restriction points, in the cell-division cycle, result of loss of control at, 25–26
Rete ridges, epidermal
in lentigo simplex, 54
in solar lentigo, 41
Reticulohistiocytoma, differentiating from Spitz nevus, 171
Reticoblastoma (RB) gene product, as a gatekeeper of the G1/S cell-division cycle, 25–26
Reverse transcriptase-polymerase chain reaction (RT-PCR)
for identifying clear-cell sarcoma, 328
for identifying melanoma markers, 385
for identifying tyrosinase mRNA expression, 358, 382–383
Rhabdomyosarcoma, alveolar, by metastatic melanoma, 362
RhoC gene
overexpression of, and metastatic propensity of melanomas, 30
promotion of neoplastic progression by, 21
Risk factors, for melanoma
associated with red hair and inability to tan, 29
atypical nevi as markers for, 69–72
in childhood, 140–141
in congenital melanocytic nevi, 111–112, 131–132
correlation of histologic melanocytic atypia with, 74
malignant, 238–239
melanocytic nevi, 51–52
stratification of, 69
S
S-100 protein
as a marker
for desmoplastic melanoma and desmoplastic-neurotropic melanoma, 291
for epithelioid melanomas, 14
for Spitz nevus, 171
serum levels of, and survival rates, 382–383
Satellite metastases, 357–358
Satellites, of congenital melanocytic nevi, 114, 139
Satellitosis, of lymphocytes, in invasive melanomas, 261
Schmorl stain, 13
Schwann cell, differentiating from a blue nevus, 199–200
Schwannomas, distinguishing from melanoma, 16
Sclerosing blue nevus, 204
differentiating from desmoplastic melanoma and neurotropic melanoma, 300
Seborrheic keratosis, reticulated, transition of solar lentigo to, 41
Secretory melanocytes, defined, 1
Sentinel lymph node (SLN) biopsy
to assess atypical Spitz-like tumors, 163
in conjunction with excisional biopsy, 11
prognosis indicated by the results of, 385
for staging risk for regional melanoma metastases, 357–358
status from, and prognosis, 375
Shave biopsy, 11–12
Shoulder phenomenon, in atypical nevus architecture, 75–76
Signaling pathway, for the melanocortin1 receptor, 28
INDEX

405

Signet-ring cell melanoma, 334
Signet-ring cell morphology, in metastatic malignant melanoma, 362
Silver-Russell syndrome, association with café-au-lait macules, 40
Silver-staining nucleolar organizer region (AgNORs). See AgNORs
Simple lentigines, differentiating from freckles, 37–38
Size
of conventional melanomas, 249–251
and histopathology
of giant congenital melanocytic nevi, 123
of larger congenital melanocytic nevi, 119–123
of small congenital melanocytic nevi, 115–119
Skin and Cancer Foundation, Sydney, Australia, 313
Skin color
and incidence of acral melanoma, 280
and incidence of subungual melanoma, 284
and number of nevi in individuals, 55
and prevalence of longitudinal melanonychia, 289
Skin excisions, routine handling of, 12
Small cell melanomas, 312–316
in childhood, histopathologic features of, 142–143
Solar intraepidermal melanocytic neoplasia, differentiating from solar melanocytic hyperplasia, 278
Solar intraepidermal melanocytic proliferations (SIMPs)
with atypia, differentiating from solar lentigo, 42–44
differentiating from solar lentigo, 41
progression to invasive melanoma, 267–268
sampling or removing lesions with features of, 256
Solar lentigines
association with melanocortin 1 receptor, 37
differentiating from freckles, 37–38
Solar lentiginous melanocytic nevi, 275–276
Solar lentiginous melanomas (LMM), desmoplastic melanoma and desmoplastic-neurotropic melanoma associated with, 290
Solar lentigo, 40, 275–280
Solar melanocytic hyperplasia (SMH), 278–280
defined, 278
Solar melanoma, 267–275
age at development of, 248
characteristics of, compared with pigmented spindle cell nevus, 189
defined, 241
differentiating from Pagetoid melanoma, 265
lentiginous pattern in, 254
similarities with pigmented spindle cell nevus, 185, 263
See also Lentigo maligna melanoma
Solar melanoma in situ, differentiating from solar lentigo, 41
Spindle cell melanocytes of Spitz nevi, 153–158
Spindle cell melanomas
desmoplastic, S-100 protein as a marker for, 14
specificity of monoclonal p75 neurotrophin receptor antibody for, 15
Spindle cell morphology, of metastatic melanomas, 362
Spindle cell nevi, pigmented, 180–185
differentiating from atypical nevi, 88
differentiating from Spitz nevi, 171
See also Spitz nevi
Spindle cells
proliferation of, in desmoplastic melanoma and desmoplastic-neurotropic melanoma, 291
in solar melanoma, differentiating from PSCNs, 276–277
Spindle cell squamous carcinoma, distinguishing from desmoplastic melanomas, 301
Spitz nevi, 148–198
combined, 98–100
continuum of histologic features with pigmented spindle cell nevus, 181
differentiating from atypical nevi, 88
hyalinizing, 178
melanomas simulating, in children, 144
Pagetoid variant, differentiating from conventional melanomas, 263
relationship with ordinary nevi in melanocytic nevi with phenotypic heterogeneity, 227–228
Spitzoid melanoma, 313–319
Spitz tumors
atypical, 160–171
defined, 148–149
differentiating from desmoplastic melanoma and neurotropic melanoma, 300
differentiating from nodular melanomas, 267
Sporadic melanoma, gene changes in, 21
Squamous carcinoma, spindle cell, distinguishing from desmoplastic melanomas, 301
Squamous epithelium, organization patterns within, in conventional melanomas, 251
Stage III melanoma, prognostic factors for, 383–385
Staghorn-like vascular pattern, in metastatic melanomas, 363
Staging system, for melanoma, 373. See also American Joint Committee on Cancer
Standardized morbidity ratio (SMR), of patients with giant congenital melanocytic nevi, 113
Starburst cells, in solar melanomas, 271–274
Stroma, 53–54
Stromal fibrotic reaction, in vulvar nevi, 98
Subcutaneous fat, extension of nevus cells into, 120
in congenital nevi, 118
Subungual melanoma (SUM), 249, 284–287
Sunlight, exposure to intermittent, and conventional melanomas, 244–248
protection against the effects of, by melanin, 1
as a risk factor for malignant melanoma, 239
as a risk factor for small cell melanoma, 313
Superficial spreading melanoma, 243
Surgical margins, interpretation of, 279
Survival rate
in clear-cell sarcoma, 327–328
in desmoplastic melanoma, 300
in locally recurrent melanoma, 381
in metastatic malignant melanoma, 357
Sutton’s nevus. See Halo nevus
Symmetry, of Spitz nevi, 157–158
T
T311 antibody to tyrosinase, as a marker for melanocytes, 15
Target blue nevus, 220
T-cells, mediation of antitumor immunity by, 31
Telangiectasia, in Spitz nevi, 160
Territorial behavior, of melanocytes of the human epidermis, 2–3
Theque. See Junctional nest
Thickness of a primary tumor, and prognosis, 373–375
Tisch nodules (pigmented hamartomas of the iris), diagnostic of neurofibromatosis, 40
Tissue processing, for biopsies of melanocytic lesions, 12–13
Tissue regeneration, proliferation of epidermal melanocytes in response to, 3
Tubular Spitz nevus, 180
Tumoral melanosis, regression in, 342–343
Tumor cells
dissociation of, in metastatic melanoma mimicking other neoplasms, 362
type of, and prognosis in malignant melanoma, 379
Tumor-infiltrating lymphocytes (TILs), 261
presence of, and prognosis in malignant melanoma, 378
Tumor invasion, depth of, and prognosis, 374–375
Tumor necrosis factor (TNF) transmembrane family, role in apoptosis in melanoma cells, 30–31
Tumor-suppressor genes
CDKN2A and ARF, 21
control of metastasis by, 30
loss-of-function mutation of, in melanomas, 20
p14ARF, structure and function of, 26
Tumor vascularity, and prognosis, in malignant melanoma, 379
Tumor volume, and prognosis, 379
21N antibody, specificity of, for mammary Paget’s disease, 265
Twin data
concordance of nevus phenotype between identical twins, 56
indicating genetic control of growth of nevi, 52
Type A nevus ceoosk 61
inverted, 98–100, 228–230
See also Epithelioid melanocytes
Type B nevus cells, 61
Type C nevus cells, 61
in the dermal component, 66
Tyrosinase
activity of, demonstration with the DOPA oxidase technique, 13–14
blood levels of, measuring to predict clinical relapse, 382–383
for recognizing metastatic tumor deposits in sentinel lymph nodes, 358
role of, in melanogenesis, 1
T311 antibody to, as a marker for melanocytes, 15
Tyrosinase-related protein 1 (TRP-1; gp75), as a melanocyte differentiation marker, 15
L-Tyrosine, substrate for the melanin pathway, 1
U
Ulceration of the primary tumor and prognosis, 375–376
in stage III disease, 385
Ultraviolet light (UV light)
effect of, on development of nevi, 52
response to mediation by the melanocortin 1 receptor, 21
proliferation of epidermal melanocytes, 3
upregulation of melanocortins in the skin, 28
See also Sunlight, exposure to
Ultraviolet radiation (UV radiation), signature mutations of, involving C to T transitions, 24
Uniformity, of cells and nuclei of Spitz nevi, 154–157
V
Variants
cytologic, of melanocytes in nevi, 7, 89–102
of melanomas, 241–242
and histomorphologic alterations, 328–336
morphological and cytological, 289–328
morphologic, of nevoid melanoma, 304–305
of Spitz nevus, 171, 178–180
Pagetoid, 263
Vascular invasion, and prognosis in malignant melanoma, 377
Verrucous melanoma, 311–312
Vertical growth phase (VGP), of melanoma, 242–243
Vimentin, of melanocytes, electron micrographs of, 5
Visceral blue nevi, 220
Vulvar lentigo, 48
W
Warthin-Starry stain, 13
Watson syndrome, association with café-au-lait macules, 40
Westerhof syndrome, association of café-au-lait macules with, 40
X
Xanthogranuloma, differentiating from Spitz nevus, 171
Xeroderma pigmentosum (XP) lentiginous lesions associated with, 267
melanomas diagnosed in patients with, 141–142
solar lentigines in, 41
Z
Zonation, in Spitz nevi, 158–159